153 related articles for article (PubMed ID: 34655411)
1. CD30 Expression in Oral and Oropharyngeal Diffuse Large B Cell Lymphoma, not Otherwise Specified.
Morais-Perdigão AL; Rodrigues-Fernandes CI; Araújo GR; Soares CD; de Andrade BAB; Martins MD; Vargas PA; Pontes HAR; Pires FR; Burbano RMR; Fonseca FP
Head Neck Pathol; 2022 Jun; 16(2):476-485. PubMed ID: 34655411
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and prognostic significance of CD30 expression in
Salas MQ; Climent F; Tapia G; DomingoDomènech E; Mercadal S; Oliveira AC; Aguilera C; Olga G; Moreno Velázquez M; Andrade-Campos M; Encuentra M; Fernández de Sevilla A; Sureda A; Sancho JM; González-Barca E
Biomarkers; 2020 Feb; 25(1):69-75. PubMed ID: 31752540
[No Abstract] [Full Text] [Related]
3. Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.
Rodrigues-Fernandes CI; Abreu LG; Radhakrishnan R; Perez DEDC; Amaral-Silva GK; Gondak RO; Rahimi S; Brennan PA; Fonseca FP; Vargas PA
J Oral Pathol Med; 2021 Jul; 50(6):587-593. PubMed ID: 34101913
[TBL] [Abstract][Full Text] [Related]
4. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
[TBL] [Abstract][Full Text] [Related]
5. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract][Full Text] [Related]
7. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
[TBL] [Abstract][Full Text] [Related]
8. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.
Gong QX; Wang Z; Liu C; Li X; Lu TX; Liang JH; Xu W; Li JY; Zhang ZH
J Clin Pathol; 2018 Sep; 71(9):795-801. PubMed ID: 29666157
[TBL] [Abstract][Full Text] [Related]
9. [ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases].
Wu WN; Xiang CX; Ma DS; Liu GZ; Liu H
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):506-511. PubMed ID: 35673721
[No Abstract] [Full Text] [Related]
10. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study.
Carbone A; Dolcetti R; Gloghini A; Maestro R; Vaccher E; di Luca D; Tirelli U; Boiocchi M
Hum Pathol; 1996 Feb; 27(2):133-46. PubMed ID: 8617454
[TBL] [Abstract][Full Text] [Related]
11. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
Slack GW; Steidl C; Sehn LH; Gascoyne RD
Br J Haematol; 2014 Dec; 167(5):608-17. PubMed ID: 25135752
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
14. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.
Castillo JJ; Beltran BE; Miranda RN; Young KH; Chavez JC; Sotomayor EM
Am J Hematol; 2018 Jul; 93(7):953-962. PubMed ID: 29984868
[TBL] [Abstract][Full Text] [Related]
15. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
Skacel M; Ross CW; Hsi ED
Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological analysis of oral diffuse large B-cell lymphoma, NOS: A systematic review.
Rodrigues-Fernandes CI; de Souza LL; Santos-Costa SFD; Pontes HAR; de Almeida OP; Vargas PA; Henao JR; Rahimi S; Brennan PA; Fonseca FP
J Oral Pathol Med; 2019 Mar; 48(3):185-191. PubMed ID: 30414287
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of CD30 Expression in Aggressive B-Cell Lymphomas.
Malysz J; Erdman P; Klapper J; Zhu J; Creer M; Bayerl MG
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):429-33. PubMed ID: 27521276
[TBL] [Abstract][Full Text] [Related]
18. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
19. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression.
Foda AAM; Atia T; Sakr HI; Abd Elaziz Ahmed Elnaghi K; Abdelhay WM; Enan ET
J Evid Based Integr Med; 2023; 28():2515690X231198315. PubMed ID: 37654084
[No Abstract] [Full Text] [Related]
[Next] [New Search]
